Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Poll|June 13, 2014
Lyme Disease? Bull’s-Eye!
Erythema migrans, the characteristic rash of Lyme disease, often has a bull’s-eye appearance. Which of the following additional factors can help the diagnosis?
Advertisement
Erythema migrans, the characteristic rash of Lyme disease, often has a bull’s-eye appearance.
Which of the following additional factors can help the diagnosis?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5